Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

It's a companion shot to Merck's Vaxneuvance (formerly V114), which covers 15 serotypes and was approved by the FDA last year as a rival to Pfizer's Prevnar 13 and newer Prevnar 20 vaccines, which ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

In this photo illustration, the Merck & Co., Inc. logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor ...

Merck ( MRK 0.53%) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males ...

Merck’s (NYSE:MRK) human papillomavirus (HPV) vaccine Gardasil 9 has met key efficacy goals in a pivotal late-stage trial involving Japanese males ages 16 to 26 years. The Phase 3 V503-064 trial ...

NEW YORK -- U.S. pharmaceutical company Moderna could have a vaccine to treat melanoma, a form of skin cancer, on the market ...

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...